Trial Profile
Phase 1/2 Study to Determine the Safety, Pharmacokinetics, and Efficacy of Single Agent CC-122 and the Combinations of CC-122 and Ibrutinib and CC-122 and Obinutuzumab in Subjects With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 22 Sep 2021
Price :
$35
*
At a glance
- Drugs Avadomide (Primary) ; Ibrutinib; Obinutuzumab
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions
- Acronyms ENHANCE
- Sponsors Celgene Corporation
- 24 Sep 2020 Status changed from active, no longer recruiting to completed.
- 09 Jun 2020 Planned primary completion date changed from 9 Jun 2020 to 7 Jul 2020.
- 18 Apr 2020 This trial has been completed in Austria according to European Clinical Trials Database record.